Elocon: Advanced Topical Corticosteroid for Effective Dermatitis Control
| Product dosage: 1mg | |||
|---|---|---|---|
| Package (num) | Per bottle | Price | Buy |
| 1 | $40.17 | $40.17 (0%) | 🛒 Add to cart |
| 2 | $30.13 | $80.34 $60.26 (25%) | 🛒 Add to cart |
| 3 | $26.78 | $120.51 $80.34 (33%) | 🛒 Add to cart |
| 4 | $25.11 | $160.69 $100.43 (38%) | 🛒 Add to cart |
| 5 | $24.10 | $200.86 $120.51 (40%) | 🛒 Add to cart |
| 6 | $23.43 | $241.03 $140.60 (42%) | 🛒 Add to cart |
| 7 | $22.96 | $281.20 $160.69 (43%) | 🛒 Add to cart |
| 8 | $21.34 | $321.37 $170.73 (47%) | 🛒 Add to cart |
| 9 | $20.09 | $361.54 $180.77 (50%) | 🛒 Add to cart |
| 10 | $19.08
Best per bottle | $401.71 $190.81 (52%) | 🛒 Add to cart |
Elocon (mometasone furoate) is a high-potency topical corticosteroid formulation designed for the targeted treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. As a class IV corticosteroid, it offers a favorable balance of efficacy and safety, making it a cornerstone in dermatological practice for managing conditions such as atopic dermatitis, psoriasis, and allergic contact dermatitis. Its optimized vehicle system enhances drug delivery while minimizing systemic absorption, providing clinicians with a reliable option for both acute flare management and maintenance therapy. With decades of clinical evidence supporting its use, Elocon represents a sophisticated therapeutic choice for patients requiring potent anti-inflammatory action with minimized side effect profiles.
Features
- Contains mometasone furoate 0.1% as the active pharmaceutical ingredient
- Available in multiple formulations: cream, ointment, and lotion for tailored application
- Hydrocarbon-based vehicle system optimized for enhanced skin penetration
- Alcohol-free lotion formulation suitable for scalp and hairy areas
- Non-comedogenic and hypoallergenic base materials
- pH-balanced to match physiological skin conditions
- Preservative-free ointment formulation for sensitive skin
- Rapid absorption with minimal residue or greasiness
- Stable chemical composition with extended shelf life
- Water-washable cream base for convenient application and removal
Benefits
- Provides rapid relief from inflammation, redness, and itching within 24-48 hours of application
- Reduces recurrence rates when used as directed in maintenance therapy protocols
- Minimizes systemic absorption due to optimized molecular structure and vehicle design
- Offers formulation flexibility to match different body areas and disease states
- Supports skin barrier repair while controlling inflammatory processes
- Enables precise application with minimal waste through various packaging options
Common use
Elocon is primarily indicated for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. This includes moderate to severe atopic dermatitis in patients aged 2 years and older, where it demonstrates particular efficacy in reducing SCORAD (Scoring Atopic Dermatitis) indices. Plaque psoriasis patients benefit from its ability to reduce scaling, erythema, and plaque elevation, especially in smaller, localized areas. Allergic contact dermatitis responses show significant improvement, with reduction in vesiculation and lichenification. Seborrheic dermatitis, especially of the scalp, responds well to the lotion formulation. Other off-label uses include lichen planus, discoid lupus erythematosus, and nummular eczema under specialist supervision. The medication is typically employed for 2-4 week treatment courses, with periodic reassessment for longer-term management needs.
Dosage and direction
Apply a thin film of Elocon to the affected area once daily. The amount needed varies depending on the condition being treated and the body surface area involved; generally, a quantity equivalent to the tip of the finger (approximately 0.5g) is sufficient to cover an area the size of two adult palms. For cream and ointment formulations: cleanse and dry the area before application, then gently massage until absorbed. For lotion: part hair to expose scalp and apply directly to affected areas, spreading lightly. Treatment duration should not exceed 4 weeks for plaque psoriasis or 2 weeks for other dermatoses without medical reassessment. Occlusive dressings may be used for resistant plaques but require careful monitoring due to increased absorption risk. Pediatric patients (2-12 years) should use the minimal effective amount and duration.
Precautions
Elocon should not be used on rosacea, perioral dermatitis, or acne vulgaris. Avoid application to the face, groin, or axillae unless specifically directed by a physician. Use with extreme caution in patients with skin infections; concomitant antimicrobial therapy may be required. Monitor for signs of skin atrophy, telangiectasia, or hypopigmentation, especially with prolonged use. Diabetic patients should be monitored closely as corticosteroids can affect glucose metabolism. Do not use under occlusive dressings on large surface areas or for extended periods due to increased systemic absorption risk. Pregnancy Category C: use only if potential benefit justifies potential risk to fetus. Nursing mothers should not apply to breast area. Pediatric patients may demonstrate greater susceptibility to systemic toxicity.
Contraindications
Hypersensitivity to mometasone furoate or any component of the formulation. Contraindicated in patients with viral skin infections (herpes simplex, varicella). Not for ophthalmic use or application to mucous membranes. Avoid in patients with cutaneous tuberculosis. Absolute contraindication in untreated bacterial or fungal skin infections. Should not be used on ulcerated skin or open wounds. Not recommended for use in children under 2 years of age. Contraindicated in patients with widespread plaque psoriasis requiring more than 50g weekly due to adrenal suppression risk.
Possible side effect
The most common side effects include burning/stinging at application site (5-10%), pruritus (3-7%), and skin dryness (2-5%). Less frequently observed: folliculitis, acneiform eruptions, hypertrichosis. With prolonged use: skin atrophy (1-3%), striae, telangiectasia, hypopigmentation. Rare systemic effects include hypothalamic-pituitary-adrenal axis suppression, glaucoma with periocular use, and Cushing’s syndrome with excessive use. Allergic contact dermatitis occurs in <1% of patients. Rebound flare upon discontinuation may occur with abrupt cessation after prolonged use. Pediatric patients may show greater susceptibility to systemic effects including growth retardation.
Drug interaction
No formal drug interaction studies have been conducted with topical Elocon. However, theoretical interactions exist with other topical products that might enhance absorption or cause irritation. Concurrent use with other topical corticosteroids may increase systemic absorption. Use with caution alongside other medications that suppress the immune system. No known interactions with systemic medications, though patients on anticoagulants might experience increased bruising due to skin fragility. Avoid concomitant use with other topical products containing irritating substances such as alcohol or abrasives.
Missed dose
Apply as soon as remembered if within a few hours of scheduled time. If接近 the time for the next dose, skip the missed dose and resume regular schedule. Do not apply double the amount to compensate for missed application. Maintain consistent once-daily application pattern. If multiple doses are missed, contact healthcare provider for guidance on resumption strategy. Irregular application may reduce treatment efficacy and prolong resolution time.
Overdose
Topical overdose may occur from excessive application frequency or amount, or use under occlusive dressings over large areas. Symptoms include severe skin atrophy, striae, systemic corticosteroid effects including hyperglycemia, hypertension, and adrenal suppression. Treatment involves discontinuation of medication and supportive care. Acute topical overdose should be managed by washing the area thoroughly. Systemic effects may require medical monitoring and possible corticosteroid replacement therapy if adrenal suppression occurs. No specific antidote exists; treatment is symptomatic and supportive.
Storage
Store at controlled room temperature 20-25°C (68-77°F). Keep tube tightly closed when not in use. Protect from freezing and excessive heat. Do not store in bathroom where moisture levels fluctuate. Keep all medications away from children and pets. Do not use beyond expiration date printed on packaging. The lotion formulation is particularly sensitive to temperature extremes; avoid storage in vehicles during hot or cold weather. Discard any medication that shows changes in color, consistency, or odor.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Individual results may vary. Always consult with a qualified healthcare professional before starting any new medication. The prescribing physician should be aware of the patient’s complete medical history. Proper diagnosis and monitoring are essential for safe and effective use. This product should be used only as directed by a healthcare provider. Full prescribing information is available upon request from the manufacturer.
Reviews
Clinical studies demonstrate Elocon’s efficacy with 78-85% of patients showing significant improvement in physician-assessed severity scores. In a 3-week study of atopic dermatitis patients, 82% achieved clear or almost clear status with once-daily application. Pediatric studies show similar efficacy profiles with appropriate monitoring. Long-term safety data supports intermittent use for maintenance therapy. Dermatologists consistently rate Elocon highly for its favorable efficacy-to-safety ratio and formulation options. Patient satisfaction surveys indicate high levels of satisfaction with symptom control and product texture. Real-world evidence confirms clinical trial findings regarding rapid onset of action and sustained control of inflammatory symptoms.